What is the recommended diagnostic work‑up and treatment plan for pelvic tuberculosis in a reproductive‑age woman presenting with chronic pelvic pain, abnormal uterine bleeding, infertility, or a persistent pelvic mass?

Pelvic Tuberculosis: Diagnostic Work-up and Treatment

Clinical Presentation

Female genital tuberculosis should be strongly suspected in any reproductive-age woman presenting with menstrual irregularities, chronic abdominopelvic pain, infertility, or a persistent pelvic mass. 1, 2

Key Clinical Features to Elicit

• Menstrual disturbances are among the most common presentations, occurring alongside abdominopelvic pain and infertility 1
• Infertility is a hallmark presentation, as many patients have indolent disease discovered only during infertility evaluation 2
• Abnormal vaginal discharge may be present 2
• Chronic pelvic pain that is persistent and unexplained by other common gynecologic conditions 1, 2
• History of pulmonary or extrapulmonary tuberculosis, as genital TB is usually secondary to infection elsewhere in the body, spreading via hematogenous or lymphatic routes 2, 3

Critical Pitfall

Up to 4.6% of pelvic TB cases present with misleading clinical and radiologic findings that mimic malignancy, leading to unnecessary aggressive surgical management. 1 Maintain high clinical suspicion even when imaging suggests neoplasm.

---

Diagnostic Work-up

Physical Examination

• Perform bimanual pelvic examination to assess for adnexal masses, tenderness, or cervical motion tenderness 4
• Evaluate for abdominopelvic masses and peritoneal signs 1
• Rule out other causes of chronic pelvic pain including endometriosis, pelvic inflammatory disease, and bladder pain syndrome 5, 4

Laboratory Investigations

The diagnosis of pelvic TB relies on a composite reference standard, as no single test has adequate sensitivity. 6

Microbiological Testing

• Endometrial aspirate or biopsy is the primary specimen for diagnosis, as the endometrium is the most commonly affected site (70% of cases) 6, 3
• GeneXpert MTB/RIF on endometrial or peritoneal tissue has significantly improved diagnostic sensitivity compared to traditional methods 6
• Acid-fast bacilli (AFB) microscopy and culture from endometrial tissue, though positive in only 42.6% of histologically confirmed cases 1
• AFB detection rates vary by site: ovary has the highest positivity, followed by fallopian tube, endometrium, and cervix 1

Histopathological Examination

• Endometrial biopsy demonstrating epithelioid granulomas is a key diagnostic finding 6, 3
• Early-stage granulomas are found in 53.3% of tuberculous endometritis cases, often with low AFB positivity 1
• Peritoneal biopsy obtained during laparoscopy can provide additional diagnostic material 6

Endoscopic Evaluation

• Laparoscopy or hysteroscopy showing definite or probable findings of genital TB contributes to the composite reference standard 6
• Direct visualization of the fallopian tubes (affected in 90% of cases) and ovaries (affected in 25% of cases) 3

Additional Testing

• Rule out active pulmonary TB with chest imaging, as genital TB is usually secondary 2, 3
• Tuberculin skin testing may support the diagnosis but is not specific 7
• Exclude urinary tract TB with imaging studies and urine AFB testing, particularly in patients with bladder symptoms 8

Composite Reference Standard Approach

Diagnosis is established by combining:

• AFB microscopy or culture positivity, OR
• Positive GeneXpert MTB/RIF, OR
• Epithelioid granulomas on endometrial/peritoneal biopsy, OR
• Definite/probable laparoscopic or hysteroscopic findings of genital TB 6

---

Treatment Plan

Drug-Sensitive Pelvic Tuberculosis

The standard treatment regimen consists of a 2-month intensive phase with rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) given orally daily, followed by a 4-month continuation phase with rifampicin, isoniazid, and ethambutol (RHE) given orally daily, for a total duration of 6 months. 2, 6, 3

This represents the current National Tuberculosis Elimination Program (NTEP) protocol, which has eliminated the previous categorization system 6.

Dosing Considerations

• Standard adult dosing follows established tuberculosis treatment guidelines 9, 10
• Pyridoxine (vitamin B6) supplementation should be provided to prevent isoniazid-induced peripheral neuropathy 10

Multi-Drug-Resistant (MDR) Pelvic Tuberculosis

For confirmed MDR-TB, use either:

• Shorter MDR-TB regimen: 9-11 months with reserved second-line drugs, OR
• Longer MDR-TB regimen: 18-20 months with reserved second-line drugs 6, 3

Never add a single drug to a failing regimen, as this creates de facto monotherapy and promotes further resistance. Always add ≥2 drugs to which the organism is susceptible 7.

Special Populations

Pregnancy

• Treatment should be initiated immediately when pelvic TB is diagnosed in pregnancy, as the risk to the fetus from untreated disease outweighs medication risks 10
• Use rifampicin, isoniazid, and ethambutol as the core regimen 10
• Pyrazinamide can be used safely during pregnancy according to WHO and IUATLD recommendations 10
• Avoid streptomycin, which causes congenital deafness 10
• Provide pyridoxine 25 mg/day to all pregnant women taking isoniazid 10
• Breastfeeding is not contraindicated during anti-tuberculosis treatment 10

Liver Disease

• Rifampicin, isoniazid, and pyrazinamide should be used if possible despite their hepatotoxic potential, given their superior efficacy 10
• Monitor liver function weekly for the first 2 weeks, then every 2 weeks during the initial 2-month intensive phase 9
• Alternative regimen for severe liver disease: rifampicin plus ethambutol for 12 months, preferably with a fluoroquinolone for the first 2 months 10

Renal Disease

• Rifampicin, isoniazid, and pyrazinamide can be given at standard doses in renal impairment 9, 10
• Ethambutol requires dose reduction and serum concentration monitoring in renal failure 9, 10

Adjunctive Corticosteroids

Corticosteroids are NOT routinely indicated for pelvic tuberculosis. 9

Corticosteroids are reserved for:

• Tuberculous meningitis (stages II and III) 9, 11
• Tuberculous pericarditis 9
• Endobronchial disease in children 9

Monitoring During Treatment

• Clinical response assessment at regular intervals (typically monthly)
• Liver function monitoring particularly in the first 2 months 9
• Adherence support is critical, as treatment failure promotes drug resistance 7

---

Management of Infertility After Treatment

Even with appropriate anti-tuberculosis treatment, pelvic TB frequently causes irreversible tubal damage and infertility. 2, 12

Fertility Options

• In vitro fertilization with embryo transfer (IVF-ET) has good success rates for patients with blocked tubes but receptive endometrium 6
• Tubal surgery may be combined with anti-tuberculosis therapy in selected cases 12
• Surrogacy or adoption should be discussed for severe Asherman's syndrome (intrauterine adhesions) 6

---

Key Clinical Pitfalls to Avoid

• Do not dismiss pelvic TB in the differential when imaging suggests malignancy; 4.6% of cases mimic cancer 1
• Do not rely solely on AFB testing; only 42.6% of histologically confirmed cases are AFB-positive 1
• Do not add a single drug to a failing regimen; always add ≥2 drugs to prevent resistance 7
• Do not delay treatment in pregnancy; the standard regimen is safe and necessary 10
• Do not forget to screen for pulmonary and urinary TB, as genital TB is usually secondary 2, 3, 8